Premium
Intraperitoneal bleomycin. Pharmacokinetics and results of a phase II trial
Author(s) -
Bitran Jacob D.
Publication year - 1985
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19851115)56:10<2420::aid-cncr2820561014>3.0.co;2-d
Subject(s) - bleomycin , medicine , pharmacokinetics , intraperitoneal injection , pharmacology , chemotherapy , gastroenterology
Bleomycin was administered in a phase II trial to 10 patients with malignant ascities. Complete responses to intraperitoneal bleomycin were observed in 6/10 patients (60%). Pharmacokinetics of serum and intraperitoneal bleomycin showed peak levels at 15 minutes with a peritoneal fluid half‐life of 4.2 ± 0.1 hours and a serum half‐life of 5.0 ± 1.2 hours. There was a 400‐fold difference in concentration when bleomycin was administered intra‐abdominally. Toxicities with intraperitoneal bleomycin were minimal. This phase II trial confirms the efficacy of intraperitoneal bleomycin; further trials appear warranted.